Status:
TERMINATED
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
Lead Sponsor:
Aclaris Therapeutics, Inc.
Conditions:
Alopecia Areata
Eligibility:
All Genders
12+ years
Phase:
PHASE2
Brief Summary
Primary: • To assess safety, tolerability and efficacy of 2 dose strengths of ATI-50002 Topical Solution, compared to vehicle in subjects with alopecia areata (AA) Secondary: • To evaluate key clin...
Detailed Description
Primary: • To assess safety, tolerability and efficacy of 2 dose strengths of ATI-50002 Topical Solution, compared to vehicle in subjects with alopecia areata (AA) Secondary: • To evaluate key clin...
Eligibility Criteria
Inclusion
- Have a clinical diagnosis of stable patchy alopecia areata (AA) defined as no current areas of spontaneous regrowth.
- Have a Severity of Alopecia Tool (SALT) score of at least 15% up to 95% total scalp hair loss determined by the study investigator at baseline.
- Have a duration of the current episode of scalp hair loss of a minimum of 6 months and a maximum of 12 years.
- If a woman of childbearing potential (WOCBP), must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2) and agree to: use a highly effective method of birth control for the duration of the study; not be planning a pregnancy during the study duration and use contraception for 30 days after last application of study medication.
Exclusion
- Females who are nursing, pregnant, or planning to become pregnant for the duration of the study and up to 30 days after the last application of study medication.
- Diffuse alopecia areata.
- Concomitant hair loss disorder (by history or physical exam) such as androgenetic alopecia or scarring alopecia (e.g., cicatricial alopecia, frontal fibrosing alopecia, etc.).
- Active skin disease on the scalp (such as psoriasis or seborrheic dermatitis) or a history of skin disease on the scalp that in the opinion of the investigator would interfere with the study assessments of efficacy or safety.
- Active scalp trauma or other condition affecting the scalp that, in the investigator's opinion, may affect the course of AA or interfere with the study conduct or evaluations.
- The presence of a permanent or difficult to remove hairpiece or wig that will, in the opinion of the investigator, interfere with study assessments if not removed at each visit.
Key Trial Info
Start Date :
November 29 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 10 2019
Estimated Enrollment :
129 Patients enrolled
Trial Details
Trial ID
NCT03354637
Start Date
November 29 2017
End Date
September 10 2019
Last Update
June 5 2020
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Aclaris Investigator Site
Encinitas, California, United States, 92024
2
Aclaris Investigator Site
Laguna Hills, California, United States, 92653
3
Aclaris Investigator Site
Redwood City, California, United States, 94063
4
Aclaris Investigator Site
Washington D.C., District of Columbia, United States, 20037